Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 29, 2018
CompletedFirst Posted
Study publicly available on registry
February 5, 2018
CompletedSeptember 25, 2024
September 1, 2024
January 29, 2018
September 23, 2024
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of advanced cancers with no standard of care option for treatment.
- Willing and able to provide written, signed informed consent.
- Use of adequate contraception.
- Negative pregnancy test.
You may not qualify if:
- Have not recovered from severe adverse events from prior therapy.
- Major surgery occurred within 28 days prior to treatment.
- Known immune system disorders such as HIV, or active hepatitis B or C infection.
- Clinically significant cardiac disease (New York Heart Association Class III or IV).
- Have received prior therapy with an oncolytic virus of any type.
- Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246).
- Have known allergy to ovalbumin or other egg products.
- Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) as assessed by the treating physician.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Florida Hospital Cancer Institute
Orlando, Florida, 32804, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 29, 2018
First Posted
February 5, 2018
Last Updated
September 25, 2024
Record last verified: 2024-09